Unlock stock picks and a broker-level newsfeed that powers Wall Street. Upgrade Now
Frankfurt - Delayed Quote EUR

Cassava Sciences, Inc. (PX91.F)

Compare
2.5730
-0.0200
(-0.77%)
At close: March 10 at 8:14:35 AM GMT+1

Key Executives

Amounts are as of December 31, 2023 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in EUR.
NameTitlePayExercisedYear Born
Mr. Richard Jon Barry CEO, President & Director 6.91k -- 1959
Mr. Eric J. Schoen Chief Financial Officer 423.58k -- 1968
Mr. R. Christopher Cook J.D. Senior VP, Company Secretary & General Counsel 391.35k -- 1965
Dr. James W. Kupiec M.D. Chief Medical Officer 400.56k -- 1954
Dr. George Thornton Ph.D. Senior Vice President of Technology -- -- --
Mr. Michael Zamloot Senior Vice President of Technical Operations -- -- --
Dr. Michael Marsman Pharm.D. Senior Vice President of Regulatory Affairs -- -- --
Ms. Freda Nassif Chief Business Officer & Chief Commercial Officer -- -- --
Jaren Landen Chief Clinical Development Officer -- -- --

Cassava Sciences, Inc.

6801 N. Capital of Texas Highway
Suite 300 Building 1
Austin, TX 78731
United States
512 501 2444 https://www.cassavasciences.com
Sector: 
Healthcare
Industry: 
Biotechnology
Full Time Employees: 
30

Description

Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2 clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's disease. The company was formerly known as Pain Therapeutics, Inc. and changed its name to Cassava Sciences, Inc. in March 2019. Cassava Sciences, Inc. was incorporated in 1998 and is based in Austin, Texas.

Corporate Governance

Cassava Sciences, Inc.’s ISS Governance QualityScore as of March 1, 2025 is 8. The pillar scores are Audit: 10; Board: 7; Shareholder Rights: 8; Compensation: 7.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.

Upcoming Events

May 8, 2025 at 10:59 AM UTC - May 12, 2025 at 12:00 PM UTC

Cassava Sciences, Inc. Earnings Date

Recent Events